Both Minerva Neurosciences Inc. (NASDAQ:NERV) and Sutro Biopharma Inc. (NASDAQ:STRO) are Biotechnology companies, competing one another. We will compare their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Minerva Neurosciences Inc.||7||0.00||N/A||-1.38||0.00|
|Sutro Biopharma Inc.||11||5.37||N/A||-1.66||0.00|
Table 1 highlights Minerva Neurosciences Inc. and Sutro Biopharma Inc.’s top-line revenue, earnings per share (EPS) and valuation.
Table 2 demonstrates the return on assets, net margins and return on equity of Minerva Neurosciences Inc. and Sutro Biopharma Inc.
|Net Margins||Return on Equity||Return on Assets|
|Minerva Neurosciences Inc.||0.00%||-56.4%||-36.9%|
|Sutro Biopharma Inc.||0.00%||0%||0%|
Minerva Neurosciences Inc. has a Current Ratio of 11.6 and a Quick Ratio of 11.6. Competitively, Sutro Biopharma Inc.’s Current Ratio is 5.7 and has 5.7 Quick Ratio. Minerva Neurosciences Inc.’s better ability to pay short and long-term obligations than Sutro Biopharma Inc.
The Ratings and Recommendations for Minerva Neurosciences Inc. and Sutro Biopharma Inc. are featured in the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Minerva Neurosciences Inc.||0||0||2||3.00|
|Sutro Biopharma Inc.||0||0||0||0.00|
The consensus price target of Minerva Neurosciences Inc. is $20, with potential upside of 191.55%.
Institutional and Insider Ownership
The shares of both Minerva Neurosciences Inc. and Sutro Biopharma Inc. are owned by institutional investors at 90.8% and 73.1% respectively. About 0.7% of Minerva Neurosciences Inc.’s share are owned by insiders. On the other hand, insiders owned about 21.23% of Sutro Biopharma Inc.’s shares.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Minerva Neurosciences Inc.||3.11%||16.29%||-8.16%||5.4%||-15.95%||-1.48%|
|Sutro Biopharma Inc.||1.9%||-4.09%||13.27%||5.52%||0%||24.94%|
For the past year Minerva Neurosciences Inc. has -1.48% weaker performance while Sutro Biopharma Inc. has 24.94% stronger performance.
Sutro Biopharma Inc. beats Minerva Neurosciences Inc. on 5 of the 8 factors.
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The companyÂ’s lead product candidate includes MIN-101, a compound for the treatment of patients with schizophrenia that completed Phase IIb clinical trial. It also offers MIN-202, which completed Phase IIa clinical trial for treating primary insomnia, as well as completed Phase 1b used for the treatment of major depressive disorder; and MIN-117, a compound that completed Phase IIa clinical trial for the treatment of patients suffering from major depressive disorder. The companyÂ’ preclinical stage product includes MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of ParkinsonÂ’s disease. Minerva Neurosciences, Inc. has a co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of MIN-202. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.